Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ736MR)

This product GTTS-WQ736MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ736MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6239MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ4164MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ2100MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ442MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ8182MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ9549MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ5467MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ6105MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO-1959
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW